The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Opens in a new tab or window The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued ... progression of fibrocalcific aortic valve stenosis in phase I and II studies.

This research represents a significant advancement in the treatment of aortic valve stenosis. Ataciguat has the potential to substantially delay or even prevent the need for valve replacement ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...